Close Menu

NEW YORK (GenomeWeb) – Transgenomic announced today that its shares have been suspended from the Nasdaq. Beginning tomorrow, Feb. 22, the firm's shares will begin trading instead on the OTCQB exchange under the ticker "TBIO."

Earlier this month, the company received written notification from the Nasdaq that it would be delisting Transgenomic's shares as the company no longer met certain continued listing requirements. The firm was required to meet the exchange's minimum share price and shareholder equity requirements on or before Feb. 19 in order to continue trading there.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.